Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast Carcinogenesis
Background: Recent epidemiological studies demonstrate that obesity is associated with an increased risk for breast cancer in women. Increased estrogen levels are suggested as one possible explanation, but this does not fully explain the relationship between obesity and breast cancer. One alterna...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2015-10-01
|
| Series: | Middle East Journal of Cancer |
| Subjects: | |
| Online Access: | http://mejc.sums.ac.ir/index.php/mejc/article/view/272/232 |
| _version_ | 1818787295909642240 |
|---|---|
| author | Sanaa A. El-Benhawy Nadia A. Abd El Moneim Samia A. Ebeid |
| author_facet | Sanaa A. El-Benhawy Nadia A. Abd El Moneim Samia A. Ebeid |
| author_sort | Sanaa A. El-Benhawy |
| collection | DOAJ |
| description | Background: Recent epidemiological studies demonstrate that obesity is associated
with an increased risk for breast cancer in women. Increased estrogen levels are
suggested as one possible explanation, but this does not fully explain the relationship
between obesity and breast cancer. One alternative explanation is secretion by adipocytes
of metabolites, hormones and cytokines, collectively known as adipocytokines, which
regulate physiological and pathological processes. Among these adipokines are visfatin
and resistin. This study investigates whether visfatin or resistin in serum of breast cancer
patients can be used as potential diagnostic and prognostic tools for breast cancer, taking
into account clinicopathological features and anthropometric parameters.
Methods: Blood samples were collected from 70 breast cancer patients (35 obese
and 35 non-obese) and 20 healthy females matched for age and body mass index as
the control group. Serum visfatin levels were measured by enzyme linked immunosorbent
assay and serum resistin levels were measured by radioimmunoassay. Inflammatory
status was assessed by measuring C-reactive protein levels by an automated turbidimetric
analyzer.
Results: We observed highly elevated serum resistin and visfatin levels in breast
cancer patients compared to controls, independent of body mass index. Serum resistin
and visfatin levels were likely to be associated with increased breast cancer risk and
correlated with the inflammatory marker C-reactive protein.
Conclusion: Targeting resistin and visfatin inhibition can be an effective therapeutic
strategy in breast cancer by downregulating the inflammatory microenvironment in breast
tissue. Serum visfatin promises to be a novel biomarker of diagnostic and prognostic
value. Larger prospective studies are required to confirm our findings. |
| first_indexed | 2024-12-18T14:05:31Z |
| format | Article |
| id | doaj.art-5f63fb713c1a408ba9755c455d6e67c2 |
| institution | Directory Open Access Journal |
| issn | 2008-6709 2008-6687 |
| language | English |
| last_indexed | 2024-12-18T14:05:31Z |
| publishDate | 2015-10-01 |
| publisher | Shiraz University of Medical Sciences |
| record_format | Article |
| series | Middle East Journal of Cancer |
| spelling | doaj.art-5f63fb713c1a408ba9755c455d6e67c22022-12-21T21:05:15ZengShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092008-66872015-10-0164253265Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast CarcinogenesisSanaa A. El-Benhawy0Nadia A. Abd El Moneim1Samia A. Ebeid2Radiation Science Department, Medical Research Institute, Alexandria University, Alexandria, EgyptCancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, EgyptApplied Medical Chemistry Department, Medical Research Institute, Alexandria University, Alexandria, EgyptBackground: Recent epidemiological studies demonstrate that obesity is associated with an increased risk for breast cancer in women. Increased estrogen levels are suggested as one possible explanation, but this does not fully explain the relationship between obesity and breast cancer. One alternative explanation is secretion by adipocytes of metabolites, hormones and cytokines, collectively known as adipocytokines, which regulate physiological and pathological processes. Among these adipokines are visfatin and resistin. This study investigates whether visfatin or resistin in serum of breast cancer patients can be used as potential diagnostic and prognostic tools for breast cancer, taking into account clinicopathological features and anthropometric parameters. Methods: Blood samples were collected from 70 breast cancer patients (35 obese and 35 non-obese) and 20 healthy females matched for age and body mass index as the control group. Serum visfatin levels were measured by enzyme linked immunosorbent assay and serum resistin levels were measured by radioimmunoassay. Inflammatory status was assessed by measuring C-reactive protein levels by an automated turbidimetric analyzer. Results: We observed highly elevated serum resistin and visfatin levels in breast cancer patients compared to controls, independent of body mass index. Serum resistin and visfatin levels were likely to be associated with increased breast cancer risk and correlated with the inflammatory marker C-reactive protein. Conclusion: Targeting resistin and visfatin inhibition can be an effective therapeutic strategy in breast cancer by downregulating the inflammatory microenvironment in breast tissue. Serum visfatin promises to be a novel biomarker of diagnostic and prognostic value. Larger prospective studies are required to confirm our findings.http://mejc.sums.ac.ir/index.php/mejc/article/view/272/232Breast cancerVisfatinResistinPrognosis |
| spellingShingle | Sanaa A. El-Benhawy Nadia A. Abd El Moneim Samia A. Ebeid Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast Carcinogenesis Middle East Journal of Cancer Breast cancer Visfatin Resistin Prognosis |
| title | Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast Carcinogenesis |
| title_full | Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast Carcinogenesis |
| title_fullStr | Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast Carcinogenesis |
| title_full_unstemmed | Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast Carcinogenesis |
| title_short | Serum Adipocytokines (Visfatin and Resistin): New Biomarkers of Breast Carcinogenesis |
| title_sort | serum adipocytokines visfatin and resistin new biomarkers of breast carcinogenesis |
| topic | Breast cancer Visfatin Resistin Prognosis |
| url | http://mejc.sums.ac.ir/index.php/mejc/article/view/272/232 |
| work_keys_str_mv | AT sanaaaelbenhawy serumadipocytokinesvisfatinandresistinnewbiomarkersofbreastcarcinogenesis AT nadiaaabdelmoneim serumadipocytokinesvisfatinandresistinnewbiomarkersofbreastcarcinogenesis AT samiaaebeid serumadipocytokinesvisfatinandresistinnewbiomarkersofbreastcarcinogenesis |